"Lymphoma, B-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
| Descriptor ID |
D016393
|
| MeSH Number(s) |
C04.557.386.480.150 C15.604.515.569.480.150 C20.683.515.761.480.150
|
| Concept/Terms |
Lymphoma, B-Cell- Lymphoma, B-Cell
- Lymphoma, B Cell
- B-Cell Lymphoma
- B Cell Lymphoma
- B-Cell Lymphomas
- Lymphomas, B-Cell
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, B-Cell".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, B-Cell".
This graph shows the total number of publications written about "Lymphoma, B-Cell" by people in this website by year, and whether "Lymphoma, B-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 1 | 3 |
| 1995 | 0 | 1 | 1 |
| 1996 | 8 | 0 | 8 |
| 1997 | 4 | 2 | 6 |
| 1998 | 9 | 3 | 12 |
| 1999 | 8 | 2 | 10 |
| 2000 | 7 | 6 | 13 |
| 2001 | 15 | 2 | 17 |
| 2002 | 14 | 6 | 20 |
| 2003 | 8 | 5 | 13 |
| 2004 | 10 | 3 | 13 |
| 2005 | 6 | 6 | 12 |
| 2006 | 20 | 9 | 29 |
| 2007 | 22 | 4 | 26 |
| 2008 | 6 | 0 | 6 |
| 2009 | 4 | 3 | 7 |
| 2010 | 7 | 5 | 12 |
| 2011 | 14 | 1 | 15 |
| 2012 | 10 | 2 | 12 |
| 2013 | 15 | 3 | 18 |
| 2014 | 15 | 0 | 15 |
| 2015 | 20 | 1 | 21 |
| 2016 | 9 | 1 | 10 |
| 2017 | 13 | 1 | 14 |
| 2018 | 12 | 0 | 12 |
| 2019 | 10 | 1 | 11 |
| 2020 | 17 | 0 | 17 |
| 2021 | 19 | 3 | 22 |
| 2022 | 13 | 0 | 13 |
| 2023 | 26 | 0 | 26 |
| 2024 | 10 | 2 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma, B-Cell" by people in Profiles.
-
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia. Nat Rev Clin Oncol. 2024 Dec; 21(12):867-887.
-
Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled Trial. JAMA Oncol. 2024 Sep 01; 10(9):1195-1203.
-
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy. Blood Adv. 2024 05 28; 8(10):2592-2599.
-
Analysis of hepatitis B virus infection in 1424 patients with different pathological types of lymphoma (2018-2022): A real-world, retrospective study. Cancer Med. 2024 May; 13(10):e7284.
-
Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy. Haematologica. 2024 05 01; 109(5):1460-1468.
-
Thymoma with aberrant expression of CD20: a potential diagnostic pitfall of B-cell lymphoma. Blood. 2024 04 11; 143(15):1551.
-
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. J Clin Oncol. 2024 Jul 01; 42(19):2250-2256.
-
SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. Cancer Cell. 2024 Apr 08; 42(4):605-622.e11.
-
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Am J Hematol. 2024 04; 99(4):586-595.
-
Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissues: B-cell Neoplasms. Mod Pathol. 2024 Apr; 37(4):100441.